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Background
A number of studies have suggested that CD8 T cells play
an important role in control of HIV/SIV replication.
Recently, it has been shown that CD8 T cells taken from
HIV-positive long term non-progressors are more effi-
ciently cytotoxic than those from rapid progressors. We
therefore endeavored to test vaccine adjuvants for their
ability to generate antigen specific CD8 T cells with a sig-
nificant capacity for cytolytic degranulation. The adju-
vants tested for this purpose were IL-12 and IL-28B.
Methods
Animals were immunized using either a multi-clade con-
sensus HIV Gag construct or multi-clade consensus HIV
Pol construct, with or without adjuvant. All animals
received electroporation during the immunization proc-
ess using the Cellectra device manufactured by VGX Phar-
maceuticals.
Results
In mice, the inclusion of either adjuvant increased anti-
gen-specific IFNgamma ELISpot numbers 3 to 4 fold over
antigen alone and lead to significant differences in anti-
gen-specific Perforin upregulation. Both IL-12 and IL-28B
were able to induce 100% protection from death associ-
ated with infection following a lethal influenza challenge,
suggesting both adjuvants may induce potent cellular
immune responses. However, only IL-28B lead to a signif-
icant increase in degranulation as measured by CD107a
expression when compared with antigen alone, suggesting
this cytokine has more potent cytotoxicity-inducing
affects than IL-12. In macaques, both IL-12 and IL-28B
augmented IFNgamma ELISpot results two-fold over anti-
gen alone. Similarly to what was seen in mice, however,
only IL-28B induced a statistically significant amount of
degranulation as measured by CD107a expression when
compared to animals that did not receive adjuvant.
Conclusion
While both adjuvants augmented antigen-specific IFN-
gamma ELISpot responses, only IL-28B was able to induce
statistically significant amounts of cytolytic degranula-
tion. Therefore, further study of IL-28B as an adjuvant for
cytotoxicity is warranted.
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